newsfilter
← Latest News
PR Newswire·

Pulmatrix Announces Positive Top-Line Data Evaluating PUR1800 in Patients with Stable COPD

LEXINGTON, Mass., March 21, 2022 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ:PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ techn